Indivior Knew Suboxone Film Did Not Have Greater Child Safety Than Tablet, Grand Jury Claims
Executive Summary
Indictment alleges Indivior falsely cited concerns about pediatric exposure to tablets in discontinuing the formulation; FDA official says company tried to mislead agency and bar competition for Suboxone.
You may also be interested in...
Theranos Cases Show How DoJ Looks Beyond The FDCA In Prosecuting Drug, Device Companies
Charges under wire fraud statute carry higher maximum prison sentences and are easier to explain than FDCA misbranding charges, Department of Justice officials say in dissecting the guilty verdicts and lengthy prison sentences for former leaders of the failed blood testing start-up.
Theranos Cases Show How DoJ Looks Beyond The FDCA In Prosecuting Drug, Device Companies
Charges under wire fraud statute carry higher maximum prison sentences and are easier to explain than FDCA misbranding charges, Department of Justice officials say in dissecting the guilty verdicts and lengthy prison sentences for former leaders of the failed blood testing start-up.
Theranos Cases Show How DoJ Looks Beyond The FDCA In Prosecuting Drug, Device Companies
Charges under wire fraud statute carry higher maximum prison sentences and are easier to explain than FDCA misbranding charges, Department of Justice officials say in dissecting the guilty verdicts and lengthy prison sentences for former leaders of the failed blood testing start-up.